BRIEF-Acasti Announces Achievement Of 50% Enrollment In Pivotal Phase 3 Strive-On Safety Trial

Reuters06-28

* ACASTI ANNOUNCES ACHIEVEMENT OF 50% ENROLLMENT IN PIVOTAL PHASE 3 STRIVE-ON SAFETY TRIAL

* ACASTI PHARMA INC: ANTICIPATE RANDOMIZING ALL 100 PATIENTS IN LATE 2024 TO EARLY 2025

* ACASTI PHARMA INC: ANTICIPATE STAYING ON TRACK FOR A POTENTIAL NDA SUBMISSION TO FDA IN FIRST HALF OF CALENDAR 2025

Source text for Eikon: Further company coverage:

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2446459833?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-28 04:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2446459833","market":"us","top_or_hot":-1,"title":"BRIEF-Acasti Announces Achievement Of 50% Enrollment In Pivotal Phase 3 Strive-On Safety Trial","media":"Reuters","content":"<html><body><p><a href=\"https://laohu8.com/S/ACST\">Acasti Pharma</a> Inc   :</p><p>   * ACASTI ANNOUNCES ACHIEVEMENT OF 50% ENROLLMENT IN PIVOTAL PHASE 3 STRIVE-ON SAFETY TRIAL</p><p>   * ACASTI PHARMA INC: ANTICIPATE RANDOMIZING ALL 100 PATIENTS IN LATE 2024 TO EARLY 2025</p><p>   * ACASTI PHARMA INC:  ANTICIPATE STAYING ON TRACK FOR A POTENTIAL NDA SUBMISSION TO FDA IN FIRST HALF OF CALENDAR 2025</p><p>Source text for Eikon:    Further company coverage:   </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Acasti Announces Achievement Of 50% Enrollment In Pivotal Phase 3 Strive-On Safety Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Acasti Announces Achievement Of 50% Enrollment In Pivotal Phase 3 Strive-On Safety Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-28 04:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Acasti Pharma Inc   :   * ACASTI ANNOUNCES ACHIEVEMENT OF 50% ENROLLMENT IN PIVOTAL PHASE 3 STRIVE-ON SAFETY TRIAL   * ACASTI PHARMA INC: ANTICIPATE RANDOMIZING ALL 100 PATIENTS IN LATE 2024 TO EARLY ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1854103824.USD","symbol_name":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2446459833","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2446459833","pubTimestamp":1719520315,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Acasti Pharma Inc   :   * ACASTI ANNOUNCES ACHIEVEMENT OF 50% ENROLLMENT IN PIVOTAL PHASE 3 STRIVE-ON SAFETY TRIAL   * ACASTI PHARMA INC: ANTICIPATE RANDOMIZING ALL 100 PATIENTS IN LATE 2024 TO EARLY 2025   * ACASTI PHARMA INC:  ANTICIPATE STAYING ON TRACK FOR A POTENTIAL NDA SUBMISSION TO FDA IN FIRST HALF OF CALENDAR 2025Source text for Eikon:    Further company coverage:","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","BK4588":"碎股","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","BK4141":"半导体产品","BK4512":"苹果概念","LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","LU0124384867.USD":"贝莱德新能源基金A2","LU1861214812.USD":"Blackrock Future of Transport A2 USD","LU1861219969.SGD":"Blackrock Future of Transport A2 SGD-H","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","IE00BD6J9T35.USD":"NEUBERGER BERMAN NEXT GENERATION MOBILITY \"A\" (USD) ACC","LU1861215975.USD":"贝莱德新一代科技基金 A2","ACST":"Acasti Pharma","LU1548497426.USD":"安联环球人工智能AT Acc","BK4585":"ETF&股票定投概念","LU1861220033.SGD":"Blackrock Next Generation Technology A2 SGD-H","BK4007":"制药","LU1978683503.SGD":"Blackrock Sustainable Energy A2 SGD-H","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC"},"translate_title":"简报-Acasti宣布关键3期Strive-On安全试验入组率达到50%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACST":0.9},"content_text":"Acasti Pharma Inc   :   * ACASTI ANNOUNCES ACHIEVEMENT OF 50% ENROLLMENT IN PIVOTAL PHASE 3 STRIVE-ON SAFETY TRIAL   * ACASTI PHARMA INC: ANTICIPATE RANDOMIZING ALL 100 PATIENTS IN LATE 2024 TO EARLY 2025   * ACASTI PHARMA INC:  ANTICIPATE STAYING ON TRACK FOR A POTENTIAL NDA SUBMISSION TO FDA IN FIRST HALF OF CALENDAR 2025Source text for Eikon:    Further company coverage:","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2446459833"}